Shape-Sensing Robotic-Assisted Bronchoscopy in the Diagnosis of Pulmonary Parenchymal Lesions.
diagnostic yield
pulmonary nodule
robotic-assisted bronchoscopy
Journal
Chest
ISSN: 1931-3543
Titre abrégé: Chest
Pays: United States
ID NLM: 0231335
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
received:
18
05
2021
revised:
05
07
2021
accepted:
29
07
2021
pubmed:
14
8
2021
medline:
11
3
2022
entrez:
13
8
2021
Statut:
ppublish
Résumé
The landscape of guided bronchoscopy for the sampling of pulmonary parenchymal lesions is evolving rapidly. Shape-sensing robotic-assisted bronchoscopy (ssRAB) recently was introduced as means to allow successful sampling of traditionally challenging lesions. What are the feasibility, diagnostic yield, determinants of diagnostic sampling, and safety of ssRAB in patients with pulmonary lesions? Data from 131 consecutive ssRAB procedures performed at a US-based cancer center between October 2019 and July 2020 were captured prospectively and analyzed retrospectively. Definitions of diagnostic procedures were based on prior standards. Associations of procedure- and lesion-related factors with diagnostic yield were examined by univariate and multivariate generalized linear mixed models. A total of 159 pulmonary lesions were targeted during 131 ssRAB procedures. The median lesion size was 1.8 cm, 59.1% of lesions were in the upper lobe, and 66.7% of lesions were beyond a sixth-generation airway. The navigational success rate was 98.7%. The overall diagnostic yield was 81.7%. Lesion size of ≥ 1.8 cm and central location were associated significantly with a diagnostic procedure in the univariate analysis. In the multivariate model, lesions of ≥ 1.8 cm were more likely to be diagnostic compared with lesions < 1.8 cm, after adjusting for lung centrality (OR, 12.22; 95% CI, 1.66-90.10). The sensitivity and negative predictive value of ssRAB for primary thoracic malignancies were 79.8% and 72.4%, respectively. The overall complication rate was 3.0%, and the pneumothorax rate was 1.5%. This study was the first to provide comprehensive evidence regarding the usefulness and diagnostic yield of ssRAB in the sampling of pulmonary parenchymal lesions. ssRAB may represent a significant advancement in the ability to access and sample successfully traditionally challenging pulmonary lesions via the bronchoscopic approach, while maintaining a superb safety profile. Lesion size seems to remain the major predictor of a diagnostic procedure.
Sections du résumé
BACKGROUND
The landscape of guided bronchoscopy for the sampling of pulmonary parenchymal lesions is evolving rapidly. Shape-sensing robotic-assisted bronchoscopy (ssRAB) recently was introduced as means to allow successful sampling of traditionally challenging lesions.
RESEARCH QUESTION
What are the feasibility, diagnostic yield, determinants of diagnostic sampling, and safety of ssRAB in patients with pulmonary lesions?
STUDY DESIGN AND METHODS
Data from 131 consecutive ssRAB procedures performed at a US-based cancer center between October 2019 and July 2020 were captured prospectively and analyzed retrospectively. Definitions of diagnostic procedures were based on prior standards. Associations of procedure- and lesion-related factors with diagnostic yield were examined by univariate and multivariate generalized linear mixed models.
RESULTS
A total of 159 pulmonary lesions were targeted during 131 ssRAB procedures. The median lesion size was 1.8 cm, 59.1% of lesions were in the upper lobe, and 66.7% of lesions were beyond a sixth-generation airway. The navigational success rate was 98.7%. The overall diagnostic yield was 81.7%. Lesion size of ≥ 1.8 cm and central location were associated significantly with a diagnostic procedure in the univariate analysis. In the multivariate model, lesions of ≥ 1.8 cm were more likely to be diagnostic compared with lesions < 1.8 cm, after adjusting for lung centrality (OR, 12.22; 95% CI, 1.66-90.10). The sensitivity and negative predictive value of ssRAB for primary thoracic malignancies were 79.8% and 72.4%, respectively. The overall complication rate was 3.0%, and the pneumothorax rate was 1.5%.
INTERPRETATION
This study was the first to provide comprehensive evidence regarding the usefulness and diagnostic yield of ssRAB in the sampling of pulmonary parenchymal lesions. ssRAB may represent a significant advancement in the ability to access and sample successfully traditionally challenging pulmonary lesions via the bronchoscopic approach, while maintaining a superb safety profile. Lesion size seems to remain the major predictor of a diagnostic procedure.
Identifiants
pubmed: 34384789
pii: S0012-3692(21)03625-4
doi: 10.1016/j.chest.2021.07.2169
pmc: PMC8941601
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
572-582Subventions
Organisme : NCI NIH HHS
ID : K08 CA245206
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009501
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2021 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.
Références
Chest. 1998 Nov;114(5):1405-10
pubmed: 9824022
Keio J Med. 1968 Mar;17(1):1-16
pubmed: 5674435
Respiration. 2020;99(1):56-61
pubmed: 31805570
Am J Respir Crit Care Med. 2013 Aug 15;188(4):503-7
pubmed: 23947517
Ann Thorac Surg. 2018 Jul;106(1):293-297
pubmed: 29486178
Am J Respir Crit Care Med. 2006 Nov 1;174(9):982-9
pubmed: 16873767
BMC Pulm Med. 2019 Dec 11;19(1):243
pubmed: 31829148
Chest. 2012 Aug;142(2):385-393
pubmed: 21980059
Chest. 2020 Jun;157(6):1656-1664
pubmed: 31978428
Chest. 2020 Mar;157(3):694-701
pubmed: 31678307
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
J Bronchology Interv Pulmonol. 2018 Oct;25(4):274-282
pubmed: 30179922
Chest. 2010 Dec;138(6):1316-21
pubmed: 20435658
Chest. 2013 May;143(5 Suppl):e78S-e92S
pubmed: 23649455
Respiration. 2009;78(3):293-300
pubmed: 19546519
ATS Sch. 2020 Dec 23;2(1):97-107
pubmed: 33870326
Eur Respir J. 2019 May 9;53(5):
pubmed: 30819811
Am J Respir Crit Care Med. 2007 Jul 1;176(1):36-41
pubmed: 17379850
Respiration. 2019;98(2):142-150
pubmed: 31352444
Med Phys. 2018 Dec;45(12):5555-5563
pubmed: 30362124
Chest. 2020 Oct;158(4):1753-1769
pubmed: 32450240
J Thorac Dis. 2015 Dec;7(Suppl 4):S304-16
pubmed: 26807279
N Engl J Med. 2015 Jul 16;373(3):243-51
pubmed: 25981554
Ann Am Thorac Soc. 2015 May;12(5):631-41
pubmed: 25965540
Radiology. 2018 Mar;286(3):1052-1061
pubmed: 29156147
Am J Respir Crit Care Med. 2015 Aug 15;192(4):468-76
pubmed: 26039792
Eur Respir J. 2011 Apr;37(4):902-10
pubmed: 20693253
Chest. 2021 Feb;159(2):845-852
pubmed: 32822675
Am J Respir Crit Care Med. 2013 Aug 1;188(3):327-33
pubmed: 23600452
Lab Invest. 1963 Feb;12:131-55
pubmed: 13999512
J Thorac Oncol. 2015 Apr;10(4):577-85
pubmed: 25514807
Chest. 2004 Sep;126(3):959-65
pubmed: 15364779
Respiration. 2014;87(2):165-76
pubmed: 24401166
Am J Respir Crit Care Med. 2016 Jan 1;193(1):68-77
pubmed: 26367186
J Thorac Dis. 2020 Dec;12(12):7683-7690
pubmed: 33447461
J Thorac Oncol. 2019 Mar;14(3):445-458
pubmed: 30476574
Sensors (Basel). 2015 Jul 15;15(7):17115-48
pubmed: 26184228
Ann Am Thorac Soc. 2014 May;11(4):578-82
pubmed: 24635641
J Bronchology Interv Pulmonol. 2018 Jul;25(3):168-175
pubmed: 29762461
Lung. 2021 Apr;199(2):177-186
pubmed: 33547938
Soft Robot. 2019 Oct;6(5):671-684
pubmed: 31241408
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571
Ann Am Thorac Soc. 2016 Sep;13(9):1586-92
pubmed: 27388116
Chest. 2018 Nov;154(5):1035-1043
pubmed: 30144421
J Thorac Dis. 2020 Jun;12(6):3279-3286
pubmed: 32642251